The Baptist Clinical Research Center participates in The Study of Tamoxifen and Raloxifene, or STAR, one of the largest breast cancer prevention studies ever. Nationally, the trial will include 22,000 postmenopausal women at increased risk of breast cancer to determine whether the osteoporosis prevention drug raloxifene (Evista) is as effective in reducing the chance of developing breast cancer as tamoxifen (Nolvadex) has proven to be.
STAR Q & A
The Baptist Clinical Research Center is part of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the network of research professionals that conducts STAR, which is supported by the National Cancer Institute (NCI). This research team has the distinction of being a study site in the nation's largest disease prevention study, the NSABP's first Breast Cancer Prevention Trial. The results of the study have shown a dramatic - nearly 50 percent - decrease in the incidence of breast cancer in women who took the drug tamoxifen.
Women who participate in STAR must be postmenopausal, at least 35 years old, and have an increased risk of breast cancer as determined by their age, family history of breast cancer, personal medical history, age at first menstrual period, and age at first live birth. They will also go through a process known as informed consent, during which they will learn about the potential benefits and risks of tamoxifen and raloxifene before deciding whether to participate in STAR.
Once a woman chooses to participate, she will be randomly assigned to receive either 20 mg tamoxifen or 60 mg raloxifene daily for five years and will have regular follow-up examinations, including mammograms and gynecologic exams.
For more information about STAR, please call Baptist Clinical Research at (901) 226-3077.
Baptist Centers for Cancer Care Genetic Testing and Counseling Center
350 N. Humphreys Blvd.
Memphis, TN 38120
(901) 227-0039
1-888-391-6558
E-mail: bccc@bmhcc.org
Top of Page
|



You May Be Interested In...

See Information Related to This Topic
|